Validation of genetic risk scores for type 2 diabetes on a Russian population sample from the biobank of the National Medical Research Center for Therapy and Preventive Medicine

Aim. To validate and evaluate the accuracy of 14 genetic risk scores (GRSs) for type 2 diabetes (T2D), created earlier in other countries, using a Russian population sample from the biobank of the National Medical Research Center for Therapy and Preventive Medicine.

Material and methods. For genetic analysis, next generation sequencing data was used on a sample from the Russian population (n=1165) based on the biobank collection. The study included 14 GRSs associated with T2D.

Results. The study demonstrated that the predictive power of 12 out of 14 GRSs for T2D was replicated in the Russian population. As quality metrics, we used the area under the ROC curve, which for models including only GRS varied from 54,49 to 59,46%, and for models including GRS, sex and age — from 77,56 to 78,75%.

Conclusion. For the first time in Russia, a study of 14 T2D GRSs developed on other populations was conducted. Twelve GRSs have been validated and can be used in the future to improve risk prediction and prevention of T2D in Russia.

1. Kopylova OV, Ershova AI, Meshkov AN, et al. Lifelong prevention of cardiovascular disease. Part I: preconceptional, prenatal and infant periods of life. Cardiovascular Therapy and Prevention. 2020;19(6):2647. (In Russ.) doi:10.15829/17288800­2020­2647.

2. Poulsen P, Kyvik KO, Vaag A, et al. Heritability of Type II (non­insulin­ dependent) diabetes mellitus and abnormal glucose tolerance — a population­ based twin study. Diabetologia. 1999;42:139­45. doi:10.1007/s001250051131.

3. Willemsen G, Ward KJ, Bell CG, et al. The concordance and heritability of type 2 diabetes in 34,166 twin pairs from international twin registers: the discordant twin (DISCOTWIN) consortium. Twin Res Hum Genet. 2015;18(6):762­71. doi:10.1017/thg.2015.83.

4. Koch S, Schmidtke J, Krawczak M, et al. Clinical utility of polygenic risk scores: a critical 2023 appraisal. J Commun Genet. 2023:1­17. doi:10.1007/s12687­023­00645­z.

5. Choi SW, Mak TSH, O’Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc. 2020;15(9):2759­72. doi:10.1038/s41596­020­0353­1.

6. Reddi HV, Wand H, Funke B, et al. Laboratory perspectives in the development of polygenic risk scores for disease: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2023;25(5):100804. doi:10.1016/j.gim.2023.100804.

7. Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015; 518(7538):197­206. doi:10.1038/nature14177.

8. Chen X, Liu C, Si S, et al. Genomic risk score provides predictive performance for type 2 diabetes in the UK biobank. Acta Diabetol. 2021;58(4):467­74. doi:10.1007/s00592­020­01650­1.

9. Vassy JL, Hivert MF, Porneala B, et al. Polygenic type 2 diabetes prediction at the limit of common variant detection. Diabetes. 2014;63(6):2172­82. doi:10.2337/db13­1663.

10. Mahajan A, Taliun D, Thurner M, et al. Fine­mapping type 2 diabetes loci to single­ variant resolution using high­density imputation and islet­ specific epigenome maps. Nat Genet. 2018;50(11):1505­13. doi:10.1038/s41588­018­0241­6.

11. Kopylova OV, Ershova AI, Pokrovskaya MS, et al. Population­ nosological research biobank of the National Medical Research Center for Therapy and Preventive Medicine: analysis of biosamples, principles of collecting and storing information. Cardiovascular Therapy and Prevention. 2021;20(8):3119. (In Russ.) doi:0.15829/1728­88002021­3119.

12. Anisimov SV, Meshkov AN, Glotov AS, et al. National association of biobanks and biobanking specialists: new community for promoting biobanking ideas and projects in Russia. Biopreserv Biobank. 2021;19:73­82. doi:10.1089/bio.2020.0049.

13. Kurilova OV, Kiseleva AV, Meshkov AN, et al. Scales for assessing the genetic risk of developing type 2 diabetes mellitus. Preventive medicine. 2021;24(12):115­22. (In Russ.) doi:10.17116/profmed202124121115.

14. Gola D, Erdmann J, Läll K, et al. Population bias in polygenic risk prediction models for coronary artery disease. Circ­ Genom Precis Me. 2020;13(6):e002932. doi:10.1161/CIRCGEN.120.002932.

15. Duncan L, Shen H, Gelaye B, et al. Analysis of polygenic risk score usage and performance in diverse human populations. Nat Commun. 2019;10(1):3328. doi:10.1038/s41467­019­11112­0.

16. Moffatt MF, Phil D, Gut IG, et al. A large­ scale, consortium­ based genomewide association study of asthma. New Engl J Med. 2010;363(13):1211­21. doi:10.1056/NEJMoa0906312.

17. Usoltsev D, Kolosov N, Rotar O, et al. Understanding complex trait susceptibilities and ethnical diversity in a sample of 4,145 Russians through analysis of clinical and genetic data. bioRxiv. 2023:2023.03.23.534000. doi:10.1101/2023.03.23.534000.

18. Sotnikova EA, Kiseleva AV, Kutsenko VA, et al. Identification of pathogenic variant burden and selection of optimal diagnostic method is a way to improve carrier screening for autosomal recessive diseases. J Pers Med. 2022;12(7):1132. doi:10.3390/jpm12071132.

19. Ramensky VE, Ershova AI, Zaicenoka M, et al. Targeted sequencing of 242 clinically important genes in the Russian population from the ivanovo region. Front Genet. 2021; 12:709419. doi:10.3389/fgene.2021.709419.

20. Boytsov SA, Chazov EI, Shlyakhto EV, et al. Epidemiology of cardiovascular diseases in different regions of Russia (ESSERF). The rationale for and design of the study. Preventive medicine. 2013;16(6):25­34. (In Russ.)

21. Walford GA, Porneala BC, Dauriz M, et al. Metabolite traits and genetic risk provide complementary information for the prediction of future type 2 diabetes. Diabetes Care. 2014;37(9):2508­14. doi:10.2337/dc14­0560.

22. Cormier H, Vigneault J, Garneau V, et al. An explained variancebased genetic risk score associated with gestational diabetes antecedent and with progression to pre‐diabetes and type 2 diabetes: a cohort study. BJOG. 2015;122(3):411­9. doi:10.1111/ 1471­0528.12937.

23. Villegas R, Goodloe RJ, McClellan BE, et al. Gene­carbohydrate and gene­fiber interactions and type 2 diabetes in diverse populations from the National Health and Nutrition Examination Surveys (NHANES) as part of the Epidemiologic Architecture for Genes Linked to Environment (EAGLE) study. BMC Genet. 2014;15:69. doi:10.1186/1471­2156­15­69.

24. Langenberg C, Sharp SJ, Franks PW, et al. Gene­lifestyle interaction and type 2 diabetes: the EPIC interact case­cohort study. PLoS Med. 2014;11(5):e1001647. doi:10.1371/journal.pmed.1001647.

25. Klimentidis YC, Chougule A, Arora A, et al. Triglyceride­ Increasing Alleles Associated with Protection against Type­2 Diabetes. PLoS Genet. 2015;11(5):e1005204. doi:10.1371/journal.pgen.1005204.

26. Liu SY, Walter S, Marden J, et al. Genetic vulnerability to diabetes and obesity: does education offset the risk? Soc Sci Med. 2015;127:150­8. doi:10.1016/j.socscimed.2014.09.009.

27. Talmud PJ, Cooper JA, Morris RW, et al. Sixty­five common genetic variants and prediction of type 2 diabetes. Diabetes. 2015;64(5):1830­40. doi:10.2337/db14­1504.

28. Leong A, Porneala B, Dupuis J, et al. Type 2 diabetes genetic predisposition, obesity, and all­cause mortality risk in the U.S.: a multiethnic analysis. Diabetes Care. 2016;39(4):539­46. doi:10.2337/dc15­2080.

29. Qi Q, Stilp AM, Sofer T, et al. Genetics of type 2 diabetes in U.S. hispanic/latino individuals: results from the hispanic community health study/study of latinos (HCHS/SOL). Diabetes. 2017;66(5):1419­25. doi:10.2337/db16­1150.

30. Liu T, Li C, Shen L, et al. Heterogeneity in effects of genetically determined adiposity on insulin resistance and type 2 diabetes: The atherosclerosis risk in communities study. J Diabetes Complicat. 2018;32(3):330­4. doi:10.1016/j.jdiacomp.2017.12.012.

31. Szczerbiński Ł, Gościk J, Bauer W, et al. Efficacy of family history, genetic risk score, and physical activity in assessing the prevalence of type 2 diabetes. Pol Arch Intern Med. 2019;129(78):442­50. doi:10.20452/pamw.14866.

32. Kaplinski M, Taylor D, Mitchell LE, et al. The association of elevated maternal genetic risk scores for hypertension, type 2 diabetes and obesity and having a child with a congenital heart defect. PloS one. 2019;14(5):e0216477. doi:10.1371/journal.pone.0216477.

33. Van der Auwera, Geraldine A, O'Connor B. Genomics in the cloud: using Docker, GATK, and WDL in Terra. O'Reilly Media. 2020. ISBN: 9781491975190.

34. Khera AV, Chaffin M, Aragam KG, et al. Genome­wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):121924. doi:10.1038/s41588­018­0183­z.

35. Scott RA, Scott LJ, Mägi R, et al. An expanded genome­wide association study of type 2 diabetes in Europeans. Diabetes. 2017;66(11):2888­902. doi:10.2337/db16­1253.

36. Morris AP, Voight BF, Teslovich TM, et al. Large­scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44(9):98190. doi:10.1038/ng.2383.